EXECUTIVE ENGAGEMENTS
OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPETITORS
BRANDS
* Login for a full stack data experience
DATE
FEB 2021
TABLES
70
PAGES
132
EDITION
6
PRICE
USD $5600
HIGHLIGHTS
SELECT PLAYERS
Advanced Cell Diagnostics, Inc.; Agena Bioscience; ANGLE plc; ApoCell, Inc.; AS One InternationalNTERNATIONAL; BioChain Institute, Inc.; Biolidics Limited; Biomatrica; Bio-Techne Corporation; BioVision, Inc.; Caltag Medsystems Limited; Cytomark Ltd.; DNA Genotek, Inc.; Epic Sciences; EpiGentek Group Inc.; F. Hoffmann-La Roche Ltd; Fluxion Biosciences, Inc.; Geno Technology Inc.; Genomax Technologies Pte Ltd.; GILUPI GmbH; LifeSpan BioSciences, Inc.; MagBio Genomics Inc.; Menarini Silicon Biosystems; MyBioSource.com; Norgen Biotek Corp.; Novus Biologicals, LLC; OraSure Technologies Inc.; Precision for Medicine, Inc.; Promega Corporation; QIAGEN; Rarecells Diagnostics SAS; RareCyte, Inc.; siemens Healthineers; SiO2 Materials Science; STEMCELL Technologies Inc.; Streck, Inc.; Thermo Fisher Scientific, Inc.; Vortex Biosciences; VyCAP B.V.
SEGMENTS
» Product Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA) » End-Use (Research, Diagnostics)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
Global Competitor Market Shares |
Rare Biomarkers Specimen Collection and Stabilization Competitor Market Share Scenario Worldwide (in %): 2020E |
Global Competitor Market Shares by Segment |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
World Current & Future Analysis for Circulating Cell Free DNA (ccfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Circulating Cell Free DNA (ccfDNA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
World Current & Future Analysis for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Circulating Tumor Cells (CTCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
World Current & Future Analysis for Exosomes / Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Exosomes / Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
World Current & Future Analysis for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
World Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
Market Facts & Figures |
USA Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
USA Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
CANADA |
Canada Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
Canada Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
JAPAN |
Japan Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
Japan Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
CHINA |
China Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
China Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
EUROPE |
Market Facts & Figures |
Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
France Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
GERMANY |
Germany Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
Germany Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
ITALY |
Italy Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
Italy Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
UNITED KINGDOM |
UK Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
UK Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
Rest of Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
REST OF WORLD |
Rest of World Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
Rest of World Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 32 |